Published in AIDS on March 08, 2002
EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients (EFV) | NCT01886404
Sex, Aging and Antiretroviral Pharmacokinetics | NCT00666055
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (2007) 4.89
Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol (2008) 1.30
Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br J Clin Pharmacol (2005) 1.28
Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother (2004) 1.18
Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother (2004) 1.09
3'-Azido-3'-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria. Biochem Pharmacol (2006) 1.02
Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother (2004) 0.97
Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. AIDS Res Hum Retroviruses (2013) 0.95
Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (2003) 0.95
Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents. Antimicrob Agents Chemother (2006) 0.92
Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management. Pharmaceutics (2011) 0.91
The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. Br J Clin Pharmacol (2015) 0.88
High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers. Antimicrob Agents Chemother (2008) 0.87
Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers. Br J Clin Pharmacol (2012) 0.86
A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients. AIDS (2009) 0.86
Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines. Can J Hosp Pharm (2012) 0.85
Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study. AIDS Res Ther (2010) 0.83
Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (2004) 0.83
Clinical evaluation of a dried blood spot assay for atazanavir. Antimicrob Agents Chemother (2010) 0.81
Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection. Antimicrob Agents Chemother (2012) 0.80
Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice. Can J Hosp Pharm (2009) 0.79
Randomized exposure-controlled trials; impact of randomization and analysis strategies. Br J Clin Pharmacol (2007) 0.79
Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir. Antimicrob Agents Chemother (2008) 0.79
Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial. Ther Drug Monit (2010) 0.78
AIDS diarrhea and antiretroviral drug concentrations: a matched-pair cohort study in Port au Prince, Haiti. Am J Trop Med Hyg (2011) 0.78
Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure. J Clin Pharmacol (2011) 0.77
Therapeutic drug monitoring in human immunodeficiency virus/acquired immunodeficiency syndrome. Quo vadis? Arch Pathol Lab Med (2003) 0.77
Neurotoxic effects of AZT on developing and adult neurogenesis. Front Neurosci (2015) 0.75
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med (2004) 13.55
Long-term consequences of kidney donation. N Engl J Med (2009) 10.17
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med (2009) 8.45
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A (2014) 2.95
Collagen deposition limits immune reconstitution in the gut. J Infect Dis (2008) 2.85
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood (2013) 2.72
Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest (2011) 2.55
Impact of randomized trial results on acute lung injury ventilator therapy in teaching hospitals. Am J Respir Crit Care Med (2003) 2.52
Critical role of CD4 T cells in maintaining lymphoid tissue structure for immune cell homeostasis and reconstitution. Blood (2012) 2.20
Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal (2011) 2.10
A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J Infect Dis (2005) 2.09
The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis (2004) 2.03
Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS (2009) 1.95
Lymphoid tissue damage in HIV-1 infection depletes naïve T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog (2012) 1.91
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses (2012) 1.89
Microarray analysis of lymphatic tissue reveals stage-specific, gene expression signatures in HIV-1 infection. J Immunol (2009) 1.87
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.78
Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS (2007) 1.72
HIV-1 subtype diversity in Minnesota. J Infect Dis (2005) 1.63
High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy. Clin Infect Dis (2010) 1.58
Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS (2003) 1.51
The effects of mindfulness-based stress reduction on sleep disturbance: a systematic review. Explore (NY) (2007) 1.50
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr (2008) 1.49
High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis (2010) 1.46
Satisfaction With Life Among Living Kidney Donors: A RELIVE Study of Long-Term Donor Outcomes. Transplantation (2014) 1.45
Demographic, clinical, and virologic characteristics of African-born persons with HIV/AIDS in a Minnesota hospital. AIDS Patient Care STDS (2007) 1.45
Blockade of HERG channels by HIV protease inhibitors. Lancet (2005) 1.44
The brief serenity scale: a psychometric analysis of a measure of spirituality and well-being. J Holist Nurs (2009) 1.43
Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr (2008) 1.43
Review and management of drug interactions with boceprevir and telaprevir. Hepatology (2012) 1.42
Comparison of generic zidovudine + lamivudine (Cipla, Duovir) and the GlaxoSmithKline brand (Combivir) tablets. J Acquir Immune Defic Syndr (2004) 1.42
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother (2008) 1.41
Untreated HIV infection and large and small artery elasticity. J Acquir Immune Defic Syndr (2009) 1.41
Lymphoid tissue structure and HIV-1 infection: life or death for T cells. Trends Immunol (2012) 1.39
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther (2007) 1.37
The role of collagen deposition in depleting CD4+ T cells and limiting reconstitution in HIV-1 and SIV infections through damage to the secondary lymphoid organ niche. Semin Immunol (2008) 1.35
Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet (2009) 1.34
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr (2013) 1.33
Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. J Acquir Immune Defic Syndr (2005) 1.33
Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol (2010) 1.32
Clinically important drug-disease interactions and their prevalence in older adults. Clin Ther (2006) 1.30
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis (2004) 1.30
Use of inappropriate prescription drugs by older people. J Am Geriatr Soc (2002) 1.30
Impact of censoring data below an arbitrary quantification limit on structural model misspecification. J Pharmacokinet Pharmacodyn (2007) 1.30
Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol (2011) 1.29
Changes in the Body Image and Relationship Scale following a one-year strength training trial for breast cancer survivors with or at risk for lymphedema. Breast Cancer Res Treat (2009) 1.28
Physical Activity and Lymphedema (the PAL trial): assessing the safety of progressive strength training in breast cancer survivors. Contemp Clin Trials (2009) 1.27
Impact of inappropriate drug use on mortality and functional status in representative community dwelling elders. Med Care (2002) 1.26
Ongoing sexually transmitted disease acquisition and risk-taking behavior among US HIV-infected patients in primary care: implications for prevention interventions. Sex Transm Dis (2012) 1.23
Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther (2012) 1.22
Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the era of effective therapy (the SUN study). Sex Transm Dis (2011) 1.21
Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. AIDS (2014) 1.19
Overcoming pharmacologic sanctuaries. Curr Opin HIV AIDS (2013) 1.17
A comprehensive approach to percutaneous injury prevention during phlebotomy: results of a multicenter study, 1993-1995. Infect Control Hosp Epidemiol (2003) 1.16
Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.16
Design of control-group conditions in clinical trials of behavioral interventions. J Nurs Scholarsh (2007) 1.14
Abnormal presence of semimature dendritic cells that induce regulatory T cells in HIV-infected subjects. J Infect Dis (2006) 1.14
Addressing the issue of channeling bias in observational studies with propensity scores analysis. Res Social Adm Pharm (2006) 1.14
Longitudinal impact of mindfulness meditation on illness burden in solid-organ transplant recipients. Prog Transplant (2005) 1.11
Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS. J Pharm Biomed Anal (2013) 1.11
The study to understand the natural history of HIV and AIDS in the era of effective therapy (SUN Study). Am J Epidemiol (2008) 1.10
Impact of inappropriate drug use on health services utilization among representative older community-dwelling residents. Am J Geriatr Pharmacother (2004) 1.09
Positive selection optimizes the number and function of MHCII-restricted CD4+ T cell clones in the naive polyclonal repertoire. Proc Natl Acad Sci U S A (2009) 1.09
Psychometric properties of the activities-specific balance confidence scale and the survey of activities and fear of falling in older women. J Am Geriatr Soc (2007) 1.07
Mindfulness: a systematic review of instruments to measure an emergent patient-reported outcome (PRO). Qual Life Res (2013) 1.06
Factors associated with non-adherence to antiretroviral therapy in the SUN study. AIDS Care (2011) 1.06
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother (2010) 1.06
Host genes associated with HIV-1 replication in lymphatic tissue. J Immunol (2010) 1.05
Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr (2014) 1.05
Mixture models and subpopulation classification: a pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotype. J Pharmacokinet Pharmacodyn (2006) 1.05
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr (2014) 1.03
Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the United States. Sex Transm Dis (2012) 1.03
A role for syndecan-1 and claudin-2 in microbial translocation during HIV-1 infection. J Acquir Immune Defic Syndr (2010) 1.03
Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs (2002) 1.02
Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients. Br J Clin Pharmacol (2003) 1.02
Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. Epilepsia (2013) 1.02
Atazanavir-containing renal calculi in an HIV-infected patient. AIDS (2007) 1.01
Postpartum health of employed mothers 5 weeks after childbirth. Ann Fam Med (2006) 1.01
Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr (2014) 1.00
Antiepileptic drug use in nursing home admissions. Ann Neurol (2003) 1.00
Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses (2004) 1.00
An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.99
The body image and relationships scale: development and validation of a measure of body image in female breast cancer survivors. J Clin Oncol (2008) 0.98
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. Antivir Ther (2010) 0.97
Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures. J Acquir Immune Defic Syndr (2015) 0.96
Effects of different meal compositions and fasted state on the oral bioavailability of etravirine. Pharmacotherapy (2008) 0.96
Predictors of long-term exercise adherence in a community-based sample of older women. J Womens Health (Larchmt) (2009) 0.95
A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. Epilepsy Res (2013) 0.95
Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents. AIDS (2011) 0.94
Validation of tacrolimus equation to predict troughs using genetic and clinical factors. Pharmacogenomics (2012) 0.94
Ex vivo modeling of oral HIV transmission in human palatine tonsil. J Histochem Cytochem (2005) 0.93
Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection. Clin Pharmacol Ther (2002) 0.93
Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder. Clin Transplant (2012) 0.92